The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women-Reference-Cited by-同舟云学术

The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women

Published:2018-09-06 Issue:1 Volume:75 Page:41-49
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Elgart Anna,Zur Arik A.,Mimrod Dorit,Dror Vered,Bar-Ilan Oren,Korver Tjeerd,Spiegelstein Ofer

Funder

Teva Pharmaceutical Industries

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00228-018-2549-7/fulltext.html

Reference33 articles.

1. Bruck W, Wegner C (2011) Insight into the mechanism of laquinimod action. J Neurol Sci 306:173–179

2. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca M, Filippi M, ALLEGRO Study Group (2012) Placebo-controlled trial of oral laquinimod in multiple sclerosis. N Engl J Med 366(11):1000–1009

3. Vollmer TL, Sorensen PS, Selmaj ZF, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, BRAVO Study Group (2014) A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261(4):773–783

4. D’Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG, Laquinimod for Crohn’s Disease Investigators (2015) A phase II study of laquinimod in Crohn’s disease. Gut 64(8):1227–1235

5. Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden MR, Sehr D, Winklhofer KF, Saft C, Gold R (2017) Laquinimod treatment in the R6/2 mouse model. Sci Rep 7:4947. https://doi.org/10.1038/s41598-017-04990-1

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In situ gel-forming oil as rectally delivering platform of hydrophobic therapeutics for ulcerative colitis therapy;International Journal of Pharmaceutics;2023-07

2. Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort;Therapeutic Advances in Neurological Disorders;2022-01

3. Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs;Expert Opinion on Investigational Drugs;2020-09-02

4. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis;Neurology;2020-07-10

5. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD;Expert Review of Gastroenterology & Hepatology;2020-07-01